{"hands_on_practices": [{"introduction": "A core application of pharmacogenomics is adjusting drug dosage based on a patient's genetic profile. This practice demonstrates how to calculate a patient-specific maintenance dose for the antifungal agent voriconazole, using a known clearance value for a CYP2C19 poor metabolizer to achieve a target therapeutic concentration ([@problem_id:4679268]). This exercise reinforces the fundamental relationship between drug clearance, dosing rate, and steady-state drug levels.", "problem": "An adult patient with invasive aspergillosis is initiated on intravenous voriconazole maintenance therapy. Genotyping reveals the patient is a Cytochrome P450 2C19 (CYP2C19) poor metabolizer, and population pharmacokinetic modeling adjusted for this phenotype estimates a phenotype-specific clearance of $CL_{PM} = 2.3\\,\\text{L}\\,\\text{h}^{-1}$. Voriconazole is administered as a constant-rate intravenous infusion replaced every dosing interval, so the input over an interval is effectively zero-order. The clinical team targets a steady-state concentration (abbreviated as $C_{ss}$) equal to the trough concentration due to the flat concentration–time profile produced by constant infusion over the dosing interval. The desired $C_{ss}$ is $3.75\\,\\text{mg}\\,\\text{L}^{-1}$, and the dosing interval is $\\tau = 12\\,\\text{h}$. Assume linear pharmacokinetics within the therapeutic range despite known nonlinearity at higher exposures, and that intravenous bioavailability is $1$.\n\nUsing only fundamental mass balance at steady state and the definition of clearance, compute the maintenance dose per dosing interval required to achieve the target trough, employing the relationship $Dose = CL_{PM} \\cdot C_{ss} \\cdot \\tau$. Round your final answer to four significant figures and express it in milligrams.", "solution": "The problem requires the calculation of a maintenance dose ($D$) for intravenous voriconazole in a specific patient population. The calculation is to be based on fundamental principles of pharmacokinetics at steady state, using provided parameters.\n\nThe fundamental principle at steady state asserts that the rate of drug administration ($Rate_{in}$) is equal to the rate of drug elimination ($Rate_{out}$).\n$$Rate_{in} = Rate_{out}$$\nThe rate of drug elimination is defined as the product of the total body clearance ($CL$) and the steady-state plasma concentration ($C_{ss}$).\n$$Rate_{out} = CL \\cdot C_{ss}$$\nThe rate of administration for a drug given as a dose ($D$) over a dosing interval ($\\tau$) with an intravenous bioavailability ($F=1$) is given by:\n$$Rate_{in} = \\frac{D}{\\tau}$$\nEquating the rate of administration and the rate of elimination yields the governing equation for the maintenance dose at steady state:\n$$\\frac{D}{\\tau} = CL \\cdot C_{ss}$$\nSolving for the maintenance dose, $D$, per dosing interval gives the relationship cited in the problem statement:\n$$D = CL \\cdot C_{ss} \\cdot \\tau$$\nThe problem provides the following specific values for this patient:\nThe phenotype-specific clearance for a CYP2C19 poor metabolizer, $CL_{PM}$, is given as:\n$$CL_{PM} = 2.3\\,\\text{L}\\,\\text{h}^{-1}$$\nThe target steady-state concentration, which is approximated as the trough concentration, is:\n$$C_{ss} = 3.75\\,\\text{mg}\\,\\text{L}^{-1}$$\nThe dosing interval is:\n$$\\tau = 12\\,\\text{h}$$\nSubstituting these values into the derived equation for the dose:\n$$D = (2.3\\,\\text{L}\\,\\text{h}^{-1}) \\cdot (3.75\\,\\text{mg}\\,\\text{L}^{-1}) \\cdot (12\\,\\text{h})$$\nA dimensional analysis confirms that the units combine to yield a unit of mass (milligrams), which is appropriate for a dose:\n$$\\frac{\\text{L}}{\\text{h}} \\cdot \\frac{\\text{mg}}{\\text{L}} \\cdot \\text{h} = \\text{mg}$$\nNow, we perform the numerical calculation:\n$$D = 2.3 \\cdot 3.75 \\cdot 12 \\,\\text{mg}$$\n$$D = 8.625 \\cdot 12 \\,\\text{mg}$$\n$$D = 103.5 \\,\\text{mg}$$\nThe problem explicitly requests the final answer to be rounded to four significant figures. The calculated value, $103.5$, already contains exactly four significant figures. Therefore, no further rounding is required. The required maintenance dose is $103.5\\,\\text{mg}$ per $12$-hour interval.", "answer": "$$\\boxed{103.5}$$", "id": "4679268"}, {"introduction": "Beyond dose adjustment, pharmacogenomics is crucial for risk stratification, especially in preventing severe adverse drug reactions. This exercise guides you through using Bayes' theorem to determine the posterior risk of abacavir hypersensitivity in a patient with a positive HLA-B\\*57:01 test result ([@problem_id:4679239]). You will learn to integrate test sensitivity, specificity, and population prevalence to quantify how a genetic test refines our prediction of patient outcomes.", "problem": "A patient with Human Immunodeficiency Virus (HIV) infection is being considered for abacavir therapy. Before treatment, the patient undergoes Human Leukocyte Antigen (HLA)-B*57:01 genotyping, which returns a positive result. Assume the following scientifically grounded framework.\n\n- Let $H$ denote the event that the patient is a true carrier of HLA-B*57:01.\n- The genotyping assay has sensitivity $Se$ and specificity $Sp$, defined as $Se = P(+ \\mid H)$ and $Sp = P(- \\mid \\neg H)$.\n- The prior probability of carriage in the clinical setting is a mixture by ancestry: with probability $q$ the patient has ancestry group $A$ with allele prevalence $p_{A}$, and with probability $1 - q$ ancestry group $B$ with allele prevalence $p_{B}$. Assume the assay characteristics are invariant across groups, and the mixture implies $P(H) = q\\,p_{A} + (1-q)\\,p_{B}$.\n- If abacavir is administered, the penetrance (conditional probability of clinically confirmed abacavir hypersensitivity given genotype) is $\\pi_{1} = P(\\text{hypersensitivity} \\mid H, \\text{abacavir})$ for carriers and $\\pi_{0} = P(\\text{hypersensitivity} \\mid \\neg H, \\text{abacavir})$ for non-carriers.\n- Assume conditional independence of the hypersensitivity outcome and the test result given the true carrier status, and that the clinical decision to administer abacavir does not itself depend on unmodeled factors beyond the positive test result specified.\n\nStarting from Bayes’ theorem and the definitions above, derive the posterior toxicity risk $R_{+} = P(\\text{hypersensitivity} \\mid +, \\text{abacavir})$ as a function of $Se$, $Sp$, $q$, $p_{A}$, $p_{B}$, $\\pi_{1}$, and $\\pi_{0}$. Then, evaluate $R_{+}$ numerically for the parameters $Se = 0.997$, $Sp = 0.995$, $q = 0.6$, $p_{A} = 0.08$, $p_{B} = 0.03$, $\\pi_{1} = 0.55$, and $\\pi_{0} = 0.01$. Express the final risk as a decimal (unitless probability) and round your answer to four significant figures.", "solution": "The objective is to derive an expression for the posterior toxicity risk, $R_{+} = P(\\text{hypersensitivity} \\mid +, \\text{abacavir})$, and evaluate it numerically. Let $D$ denote the event of hypersensitivity. The decision to administer abacavir is based on the positive test result, so the condition 'abacavir' is background information for the events of interest. The risk can thus be written as $R_{+} = P(D \\mid +)$.\n\nWe can express this conditional probability using the law of total probability, conditioning on the true `HLA-B*57:01` carrier status, $H$.\n$$R_{+} = P(D \\mid +) = P(D, H \\mid +) + P(D, \\neg H \\mid +)$$\nUsing the definition of conditional probability, $P(A, B \\mid C) = P(A \\mid B, C)P(B \\mid C)$, this becomes:\n$$R_{+} = P(D \\mid H, +) P(H \\mid +) + P(D \\mid \\neg H, +) P(\\neg H \\mid +)$$\n\nThe problem states that the hypersensitivity outcome ($D$) and the test result ($+$) are conditionally independent given the true carrier status ($H$ or $\\neg H$). This implies:\n$P(D \\mid H, +) = P(D \\mid H)$\n$P(D \\mid \\neg H, +) = P(D \\mid \\neg H)$\n\nThe problem provides the penetrance values, which are the conditional probabilities of hypersensitivity given carrier status and abacavir administration:\n$\\pi_{1} = P(D \\mid H, \\text{abacavir}) = P(D \\mid H)$\n$\\pi_{0} = P(D \\mid \\neg H, \\text{abacavir}) = P(D \\mid \\neg H)$\n\nSubstituting these into the expression for $R_{+}$ yields:\n$$R_{+} = \\pi_{1} P(H \\mid +) + \\pi_{0} P(\\neg H \\mid +)$$\nSince $P(\\neg H \\mid +) = 1 - P(H \\mid +)$, we can write:\n$$R_{+} = \\pi_{1} P(H \\mid +) + \\pi_{0} (1 - P(H \\mid +))$$\n\nThe term $P(H \\mid +)$ is the posterior probability of being a carrier given a positive test result. We can find this using Bayes' theorem:\n$$P(H \\mid +) = \\frac{P(+ \\mid H) P(H)}{P(+)}$$\nTo find $P(+)$, we use the law of total probability again:\n$$P(+) = P(+ \\mid H) P(H) + P(+ \\mid \\neg H) P(\\neg H)$$\n\nThe problem provides the following terms:\n- Sensitivity: $Se = P(+ \\mid H)$\n- Specificity: $Sp = P(- \\mid \\neg H)$, which implies the false positive rate is $P(+ \\mid \\neg H) = 1 - Sp$.\n- Prior probability of being a carrier, which we will denote as $P_{H}$: $P(H) = P_{H}$.\n- Then, $P(\\neg H) = 1 - P_{H}$.\n\nSubstituting these into the expression for $P(+)$:\n$$P(+) = Se \\cdot P_{H} + (1 - Sp)(1 - P_{H})$$\nNow, we can write the full expression for $P(H \\mid +)$:\n$$P(H \\mid +) = \\frac{Se \\cdot P_{H}}{Se \\cdot P_{H} + (1 - Sp)(1 - P_{H})}$$\n\nSubstituting the expressions for $P(H \\mid +)$ and $P(\\neg H \\mid +) = \\frac{P(+ \\mid \\neg H)P(\\neg H)}{P(+)} = \\frac{(1 - Sp)(1 - P_{H})}{Se \\cdot P_{H} + (1 - Sp)(1 - P_{H})}$ back into the equation for $R_{+}$:\n$$R_{+} = \\pi_{1} \\left( \\frac{Se \\cdot P_{H}}{P(+)} \\right) + \\pi_{0} \\left( \\frac{(1 - Sp)(1 - P_{H})}{P(+)} \\right)$$\n$$R_{+} = \\frac{\\pi_{1} Se P_{H} + \\pi_{0} (1 - Sp)(1 - P_{H})}{Se P_{H} + (1 - Sp)(1 - P_{H})}$$\nThis is the final analytical expression for the posterior toxicity risk.\n\nNow, we evaluate this expression numerically. First, we calculate the prior probability of carriage, $P_{H}$, using the mixture model provided: $P_{H} = q\\,p_{A} + (1-q)\\,p_{B}$.\nGiven values are $q = 0.6$, $p_{A} = 0.08$, and $p_{B} = 0.03$.\n$$P_{H} = (0.6)(0.08) + (1 - 0.6)(0.03) = 0.048 + (0.4)(0.03) = 0.048 + 0.012 = 0.06$$\nSo, the prior probability of being a carrier is $P_{H} = 0.06$, and the probability of not being a carrier is $P(\\neg H) = 1 - P_{H} = 1 - 0.06 = 0.94$.\n\nThe other given values are:\n$Se = 0.997$\n$Sp = 0.995 \\implies 1 - Sp = 1 - 0.995 = 0.005$\n$\\pi_{1} = 0.55$\n$\\pi_{0} = 0.01$\n\nWe substitute these values into the derived formula for $R_{+}$:\n$$R_{+} = \\frac{(0.55)(0.997)(0.06) + (0.01)(0.005)(0.94)}{(0.997)(0.06) + (0.005)(0.94)}$$\nFirst, calculate the numerator:\nNumerator $= (0.55)(0.05982) + (0.01)(0.0047)$\nNumerator $= 0.032901 + 0.000047 = 0.032948$\n\nNext, calculate the denominator, which is $P(+)$:\nDenominator $= (0.997)(0.06) + (0.005)(0.94)$\nDenominator $= 0.05982 + 0.0047 = 0.06452$\n\nFinally, calculate the ratio:\n$$R_{+} = \\frac{0.032948}{0.06452} \\approx 0.51065561066$$\n\nThe problem requires the answer to be rounded to four significant figures.\n$$R_{+} \\approx 0.5107$$", "answer": "$$\\boxed{0.5107}$$", "id": "4679239"}, {"introduction": "The ultimate goal of antimicrobial therapy is to achieve a desired pharmacodynamic effect, not just a target concentration. This advanced problem challenges you to connect a genotype-dependent change in clearance to a critical pharmacodynamic target for beta-lactam antibiotics, the fraction of time the free drug concentration remains above the MIC ($fT > \\mathrm{MIC}$) ([@problem_id:4679304]). By deriving the maximal genetic effect on clearance that still permits therapeutic target attainment, you will master the integration of pharmacokinetics, pharmacodynamics, and pharmacogenomics.", "problem": "A beta-lactam antibiotic with time-dependent bacterial killing is administered as intermittent intravenous boluses into a one-compartment system with linear pharmacokinetics. Assume the following foundational facts: between doses, the total plasma concentration $C(t)$ follows first-order elimination governed by $dC/dt=-k\\,C$ with $k=\\mathrm{CL}/V$, where $\\mathrm{CL}$ is clearance and $V$ is volume of distribution; the free (unbound) concentration equals $f_u\\,C(t)$, where $f_u$ is the unbound fraction; and the pharmacodynamic driver for efficacy is the fraction of the dosing interval during which the free concentration exceeds the minimum inhibitory concentration (MIC), denoted $fT > \\mathrm{MIC}$. A standard pharmacokinetics/pharmacodynamics (PK/PD) target for serious infections with beta-lactams is $fT > \\mathrm{MIC}=\\phi^{\\ast}$ with $\\phi^{\\ast}=0.5$.\n\nConsider a patient receiving dose $D=2000\\,\\mathrm{mg}$ every $\\tau=8\\,\\mathrm{h}$ by rapid intravenous bolus. The wild-type genotype has baseline clearance $\\mathrm{CL}_0=6\\,\\mathrm{L/h}$ and volume of distribution $V=20\\,\\mathrm{L}$. Protein binding is not saturable in the relevant range and the unbound fraction is $f_u=0.70$, independent of genotype. The pathogen’s minimum inhibitory concentration is $\\mathrm{MIC}=16\\,\\mathrm{mg/L}$. Due to a renal transporter polymorphism, the patient’s clearance is multiplied by a genotype factor $g>0$ such that $\\mathrm{CL}(g)=g\\,\\mathrm{CL}_0$, with no change in $V$ or $f_u$.\n\nStarting only from the differential equation $dC/dt=-k\\,C$ with $k=\\mathrm{CL}(g)/V$ and the definitions above, derive the steady-state expression for $fT > \\mathrm{MIC}$ as a function of $g$ under multiple identical intravenous bolus doses separated by interval $\\tau$, and then determine the maximal genotype factor $g_{\\max}$ such that the standard target $fT > \\mathrm{MIC}=\\phi^{\\ast}$ is exactly met at steady state. Assume linear kinetics, superposition applies, and steady state has been achieved. Report $g_{\\max}$ as a dimensionless number, rounded to three significant figures.", "solution": "The problem asks for the derivation of the steady-state expression for the pharmacodynamic index $fT > \\mathrm{MIC}$ as a function of a genotype factor $g$, and then to find the maximal value of this factor, $g_{\\max}$, that allows for the attainment of a specific therapeutic target.\n\nThe starting point is the differential equation for drug concentration $C(t)$ in a one-compartment model following an intravenous bolus, with first-order elimination:\n$$\n\\frac{dC}{dt} = -kC(t)\n$$\nThe solution to this equation is $C(t) = C(0)\\exp(-kt)$, where $C(0)$ is the initial concentration and $k$ is the first-order elimination rate constant. The rate constant is defined as $k = \\mathrm{CL}/V$, where $\\mathrm{CL}$ is the clearance and $V$ is the volume of distribution. The problem states that clearance is a function of the genotype factor $g$, such that $\\mathrm{CL}(g) = g\\,\\mathrm{CL}_0$. Therefore, the rate constant is also a function of $g$:\n$$\nk(g) = \\frac{\\mathrm{CL}(g)}{V} = \\frac{g\\,\\mathrm{CL}_0}{V}\n$$\nFor a regimen of intermittent intravenous bolus doses $D$ administered every $\\tau$ hours, the concentration at steady state fluctuates between a minimum (trough) concentration, $C_{\\min, ss}$, and a maximum (peak) concentration, $C_{\\max, ss}$. At steady state, the concentration just before a dose is $C_{\\min, ss}$. Immediately after the bolus dose $D$, the concentration increases by $D/V$, reaching the peak:\n$$\nC_{\\max, ss} = C_{\\min, ss} + \\frac{D}{V}\n$$\nDuring the dosing interval $\\tau$, the concentration decays from $C_{\\max, ss}$ back down to $C_{\\min, ss}$:\n$$\nC_{\\min, ss} = C_{\\max, ss} \\exp(-k\\tau)\n$$\nWe can solve this system of two equations for $C_{\\max, ss}$. Substituting the second equation into the first gives:\n$$\nC_{\\max, ss} = C_{\\max, ss} \\exp(-k\\tau) + \\frac{D}{V}\n$$\n$$\nC_{\\max, ss} (1 - \\exp(-k\\tau)) = \\frac{D}{V}\n$$\n$$\nC_{\\max, ss} = \\frac{D/V}{1 - \\exp(-k\\tau)}\n$$\nThe concentration at any time $t$ within a dosing interval at steady state (where $t=0$ is the time of the dose) is given by:\n$$\nC_{ss}(t) = C_{\\max, ss} \\exp(-kt)\n$$\nThe pharmacodynamic driver is the time for which the free (unbound) concentration, $C_{free}(t) = f_u C_{ss}(t)$, exceeds the Minimum Inhibitory Concentration ($\\mathrm{MIC}$). The duration of time over which this condition holds within one dosing interval is denoted $t_{>\\mathrm{MIC}}$. The target $fT > \\mathrm{MIC}$ is the fraction of the dosing interval for which this is true: $fT > \\mathrm{MIC} = t_{>\\mathrm{MIC}}/\\tau$.\n\nThe condition $C_{free}(t) > \\mathrm{MIC}$ is equivalent to $f_u C_{ss}(t) > \\mathrm{MIC}$. Substituting the expression for $C_{ss}(t)$:\n$$\nf_u C_{\\max, ss} \\exp(-kt) > \\mathrm{MIC}\n$$\nAssuming the peak free concentration is above the MIC ($f_u C_{\\max, ss} > \\mathrm{MIC}$), we can solve for the time $t$ for which the concentration remains above the MIC:\n$$\n\\exp(-kt) > \\frac{\\mathrm{MIC}}{f_u C_{\\max, ss}}\n$$\n$$\n-kt > \\ln\\left(\\frac{\\mathrm{MIC}}{f_u C_{\\max, ss}}\\right)\n$$\n$$\nkt < -\\ln\\left(\\frac{\\mathrm{MIC}}{f_u C_{\\max, ss}}\\right) = \\ln\\left(\\frac{f_u C_{\\max, ss}}{\\mathrm{MIC}}\\right)\n$$\n$$\nt < \\frac{1}{k} \\ln\\left(\\frac{f_u C_{\\max, ss}}{\\mathrm{MIC}}\\right)\n$$\nThus, $t_{>\\mathrm{MIC}} = \\frac{1}{k} \\ln\\left(\\frac{f_u C_{\\max, ss}}{\\mathrm{MIC}}\\right)$, provided the concentration drops below the MIC within the interval. The expression for $fT > \\mathrm{MIC}$ as a function of $g$ is obtained by substituting the expressions for $k(g)$ and $C_{\\max, ss}(g)$:\n$$\nfT > \\mathrm{MIC}(g) = \\frac{t_{>\\mathrm{MIC}}}{\\tau} = \\frac{1}{k(g)\\tau} \\ln\\left(\\frac{f_u C_{\\max, ss}(g)}{\\mathrm{MIC}}\\right)\n$$\n$$\nfT > \\mathrm{MIC}(g) = \\frac{1}{k(g)\\tau} \\ln\\left(\\frac{f_u}{\\mathrm{MIC}} \\frac{D/V}{1 - \\exp(-k(g)\\tau)}\\right)\n$$\nSubstituting $k(g) = g\\,\\mathrm{CL}_0/V$:\n$$\nfT > \\mathrm{MIC}(g) = \\frac{V}{g\\,\\mathrm{CL}_0 \\tau} \\ln\\left(\\frac{f_u D}{V \\cdot \\mathrm{MIC}} \\left( \\frac{1}{1 - \\exp\\left(-\\frac{g\\,\\mathrm{CL}_0 \\tau}{V}\\right)} \\right) \\right)\n$$\nThis is the required steady-state expression for $fT > \\mathrm{MIC}$ as a function of $g$.\n\nNext, we must find the maximal genotype factor $g_{\\max}$ for which the PK/PD target $fT > \\mathrm{MIC} = \\phi^{\\ast} = 0.5$ is met. Let $k_{\\max}$ be the elimination rate constant corresponding to $g_{\\max}$. The condition is:\n$$\n\\frac{t_{>\\mathrm{MIC}}}{\\tau} = \\phi^{\\ast} \\implies t_{>\\mathrm{MIC}} = \\phi^{\\ast}\\tau\n$$\nAt the exact time $t_{>\\mathrm{MIC}}$, the free concentration equals the MIC:\n$$\nf_u C_{ss}(t_{>\\mathrm{MIC}}) = f_u C_{\\max, ss} \\exp(-k_{\\max} t_{>\\mathrm{MIC}}) = \\mathrm{MIC}\n$$\nSubstituting $t_{>\\mathrm{MIC}} = \\phi^{\\ast}\\tau$:\n$$\nf_u C_{\\max, ss} \\exp(-k_{\\max} \\phi^{\\ast} \\tau) = \\mathrm{MIC}\n$$\nThis gives one expression for $C_{\\max, ss}$:\n$$\nC_{\\max, ss} = \\frac{\\mathrm{MIC}}{f_u} \\exp(k_{\\max} \\phi^{\\ast} \\tau)\n$$\nWe equate this with our previously derived expression for $C_{\\max, ss}$:\n$$\n\\frac{D/V}{1 - \\exp(-k_{\\max}\\tau)} = \\frac{\\mathrm{MIC}}{f_u} \\exp(k_{\\max} \\phi^{\\ast} \\tau)\n$$\nRearranging to solve for the term containing all the known parameters:\n$$\n\\frac{f_u D}{V \\cdot \\mathrm{MIC}} = \\left(1 - \\exp(-k_{\\max}\\tau)\\right) \\exp(k_{\\max} \\phi^{\\ast} \\tau) = \\exp(k_{\\max} \\phi^{\\ast} \\tau) - \\exp(k_{\\max} \\tau(\\phi^{\\ast}-1))\n$$\nThe problem specifies the target $\\phi^{\\ast} = 0.5$. Substituting this value simplifies the equation significantly:\n$$\n\\frac{f_u D}{V \\cdot \\mathrm{MIC}} = \\exp(0.5 k_{\\max} \\tau) - \\exp(-0.5 k_{\\max} \\tau)\n$$\nThe right-hand side is the definition of the hyperbolic sine function, $2\\sinh(x) = \\exp(x) - \\exp(-x)$.\n$$\n\\frac{f_u D}{V \\cdot \\mathrm{MIC}} = 2\\sinh\\left(\\frac{k_{\\max}\\tau}{2}\\right)\n$$\nWe can now solve for $k_{\\max}$:\n$$\n\\sinh\\left(\\frac{k_{\\max}\\tau}{2}\\right) = \\frac{f_u D}{2 V \\cdot \\mathrm{MIC}}\n$$\n$$\n\\frac{k_{\\max}\\tau}{2} = \\arcsinh\\left(\\frac{f_u D}{2 V \\cdot \\mathrm{MIC}}\\right)\n$$\n$$\nk_{\\max} = \\frac{2}{\\tau} \\arcsinh\\left(\\frac{f_u D}{2 V \\cdot \\mathrm{MIC}}\\right)\n$$\nFinally, we relate $k_{\\max}$ to $g_{\\max}$ using $k_{\\max} = g_{\\max}\\mathrm{CL}_0/V$:\n$$\ng_{\\max} = \\frac{V \\cdot k_{\\max}}{\\mathrm{CL}_0} = \\frac{V}{\\mathrm{CL}_0} \\left[ \\frac{2}{\\tau} \\arcsinh\\left(\\frac{f_u D}{2 V \\cdot \\mathrm{MIC}}\\right) \\right]\n$$\n$$\ng_{\\max} = \\frac{2V}{\\mathrm{CL}_0 \\tau} \\arcsinh\\left(\\frac{f_u D}{2 V \\cdot \\mathrm{MIC}}\\right)\n$$\nNow, we substitute the given numerical values: $D=2000\\,\\mathrm{mg}$, $\\tau=8\\,\\mathrm{h}$, $\\mathrm{CL}_0=6\\,\\mathrm{L/h}$, $V=20\\,\\mathrm{L}$, $f_u=0.70$, and $\\mathrm{MIC}=16\\,\\mathrm{mg/L}$.\n$$\ng_{\\max} = \\frac{2(20\\,\\mathrm{L})}{(6\\,\\mathrm{L/h})(8\\,\\mathrm{h})} \\arcsinh\\left(\\frac{(0.70)(2000\\,\\mathrm{mg})}{2(20\\,\\mathrm{L})(16\\,\\mathrm{mg/L})}\\right)\n$$\n$$\ng_{\\max} = \\frac{40}{48} \\arcsinh\\left(\\frac{1400}{640}\\right) = \\frac{5}{6} \\arcsinh\\left(\\frac{35}{16}\\right)\n$$\n$$\ng_{\\max} = \\frac{5}{6} \\arcsinh(2.1875)\n$$\nUsing the relation $\\arcsinh(x) = \\ln(x + \\sqrt{x^2+1})$:\n$$\n\\arcsinh(2.1875) \\approx \\ln(2.1875 + \\sqrt{2.1875^2 + 1}) \\approx \\ln(2.1875 + \\sqrt{4.78515625 + 1})\n$$\n$$\n\\arcsinh(2.1875) \\approx \\ln(2.1875 + \\sqrt{5.78515625}) \\approx \\ln(2.1875 + 2.405235) \\approx \\ln(4.592735) \\approx 1.52445\n$$\n$$\ng_{\\max} \\approx \\frac{5}{6} \\times 1.52445 \\approx 1.270375\n$$\nRounding to three significant figures, we get $g_{\\max} \\approx 1.27$.", "answer": "$$\n\\boxed{1.27}\n$$", "id": "4679304"}]}